Urinary 1 H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment

International Journal of Obesity

Volumn 39, Issue 7, 2015, Pages 1118-1125

  Miccheli, A ^a   Capuani, G ^a   Marini, F ^a   Tomassini, A ^a   Pratico G ^a   Ceccarelli, S ^b   Gnani, D ^b   Baviera, G ^c   Alisi, A ^b   Putignani, L ^b   Nobili, V ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c Pediatrician   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 METHYLPROPIONIC ACID; ALANINE AMINOTRANSFERASE; CREATININE; GLUCAGON LIKE PEPTIDE 1; PLACEBO; TYROSINE; VALINE; VSL3; 2 AMINO 2 METHYLPROPIONIC ACID; 2-HYDROXYISOBUTYRIC ACID; 3-AMINOISOBUTYRIC ACID; BIOLOGICAL MARKER; HYDROXYBUTYRIC ACID; PROBIOTIC AGENT;

AMINO ACID METABOLISM; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; HUMAN; INTESTINE FLORA; LIVER BIOPSY; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ULTRASOUND; URINALYSIS; CHILDHOOD OBESITY; COMPLICATION; CONTROLLED STUDY; DIET THERAPY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; FEMALE; LIVER; MALE; METABOLISM; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; URINE;

ALANINE TRANSAMINASE; AMINOISOBUTYRIC ACIDS; BIOMARKERS; BODY MASS INDEX; CHILD; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYBUTYRATES; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; NON-ALCOHOLIC FATTY LIVER DISEASE; PEDIATRIC OBESITY; PROBIOTICS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84936845643     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.40     Document Type: Article

References (42)

1. Sallis JF, Hinckson EA. Reversing the obesity epidemic in young people: building up the physical activity side of energy balance. Lancet Diabetes Endocrinol 2014; 2: 190-191.
2. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13: 40.
3. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012; 9: 152-161.
4. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636.
5. Miele L, Marrone G, Lauritano C, Cefalo C, Gasbarrini A, Day C et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des 2013; 19: 5314-5324.
6. Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013; 45: 543-551.
7. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-476.
8. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010; 50: 645-649.
9. Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014; 46: 556-560.
10. Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in nonalcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012; 2: 132.
11. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013; 13: e7233.
12. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
13. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 2012; 7: e45425.
14. Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, Palladino G et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 2011; 6: e22978.
15. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276-1285.
16. Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014; 146: 46-62.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
18. Brasili E, Mengheri E, Tomassini A, Capuani G, Roselli M, Finamore A et al. Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 induce different agerelated metabolic profiles revealed by 1H-NMR spectroscopy in urine and feces of mice. J Nutr 2013; 143: 1549-1557.
19. Fan TWM, Lane AN. Structure-based profiling of metabolites and isotopomers by NMR. Progr Nucl Magn Res Spectrosc 2008; 52: 69-117.
20. Martin FP, Sprenger N, Yap IK, Wang Y, Bibiloni R, Rochat F et al. Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res 2009; 8: 2090-2105.
21. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res 2013 41: D801-D807.
22. Smilde AK, Jansen JJ, Hoefsloot HCJ, Lamers R, Van der Greef J, Timmerman ME. ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data. Bioinformatics 2005; 21: 3043-3048.
23. Brasili E, Praticò G, Marini F, Valletta A, Capuani G, Sciubba F et al. A non-targeted metabolomics approach to evaluate the effects of biomass growth and chitosan elicitation on primary and secondary metabolism of Hypericum perforatum in vitro roots. Metabolomics 2014; 10: 1186-1196.
24. Wiklund PK, Pekkala S, Autio R, Munukka E, Xu L, Saltevo J et al. Serum metabolic profiles in overweight and obese women with and without metabolic syndrome. Diabetol Metab Syndr 2014; 6: 40.
25. Würtz P, Mäkinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J et al. Metabolic signatures of insulin resistance in 7, 098 young adults. Diabetes 2012; 61: 1372-1380.
26. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
27. Ofengand J. Ribosomal RNA pseudouridines and pseudouridine synthases. FEBS Lett 2002; 514: 17-25.
28. Charette M, Gray MW. "Pseudouridine in RNA: what, where, how, and why". IUBMB Life 2000; 49: 341-335.
29. Topp H, Schöch G. Whole-body degradation rates of transfer-, ribosomal-, and messenger ribonucleic acids and resting metabolic rate in 3-to 18-yearold humans. Pediatr Res. 2000; 47: 163-168.
30. Schoch G, Topp H, Held A, Heller-Schoch G, Ballauff A, Manz F, Sander G. Interrelation between whole-body turnover rates of RNA and protein. Eur J Clin Nutr 1990; 44: 647-658.
31. Schoch G, Topp H. Interrelations between degradation rates of RNA and protein and the energy turnover rates. In: Raiha NCR (eds). Protein Metabolism During Infancy. Raven Press: New York, NY, USA, 1994. pp 49-52.
32. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int J Mol Med 2010; 26: 471-476.
33. Topp H, Fusch G, Schöch G, Fusch C. Noninvasive markers of oxidative DNA stress, RNA degradation and protein degradation are differentially correlated with resting metabolic rate and energy intake in children and adolescents. Pediatric Res 2008; 64: 246-250.
34. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18: 371-377.
35. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
36. Calvani R, Miccheli A, Capuani G, Tomassini Miccheli A, Puccetti C, Delfini M et al. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes 2010; 34: 1095-1098.
37. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117-2122.
38. Rohwerder T, Müller RH. Biosynthesis of 2-hydroxyisobutyric acid (2-HIBA) from renewable carbon. Microb Cell Fact 2010; 9: 13.
39. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013; 288: 25088-25097.
40. Everard A, Cani PD. Gut microbiota and GLP-1. Rev Endocr Metab Disord 2014; 15: 189-196.
41. Pollitt RJ, Green A, Smith R. Excessive excretion of beta-alanine and of 3-hydroxypropionic, R-and S-3-aminoisobutyric, R-and S-3-hydroxyisobutyric and S-2-(hydroxymethyl)butyric acids probably due to a defect in the metabolism of the corresponding malonic semialdehydes. J Inherit Metab Dis 1985; 8: 75-79.
42. Roberts LD, Boström P, O'Sullivan JF, Schinzel RT, Lewis GD, Dejam A et al. Aminoisobutyric acid induces browning of white fat and hepatic oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab 2014; 19: 96-108.